Clinical trial

Initial Combination With Pioglitazone Study (0431-064)

NCT00397631

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-12-19

PhasePHASE3

Study timeline

Study start (actual)2006-12-19Date precision: day

Registry last updated2017-05-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

sitagliptin 100 mg q.d./pioglitazone 30 mg q.dDRUG

Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.DRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00397631 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.